Aziyo Biologics, Inc. (AZYO)

NASDAQ: AZYO · IEX Real-Time Price · USD
7.20
+0.50 (7.46%)
At close: Sep 29, 2022 4:30 PM
7.25
+0.05 (0.69%)
After-hours: Sep 30, 2022 4:00 PM EDT
7.46%
Market Cap 98.08M
Revenue (ttm) 46.48M
Net Income (ttm) -34.93M
Shares Out 13.62M
EPS (ttm) -2.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,403
Open 7.28
Previous Close 6.70
Day's Range 6.61 - 7.28
52-Week Range 4.10 - 7.89
Beta n/a
Analysts Buy
Price Target 10.71 (+48.8%)
Earnings Date Nov 7, 2022

About AZYO

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke fo... [Read more...]

Industry Medical Devices
IPO Date Oct 8, 2020
Employees 162
Stock Exchange NASDAQ
Ticker Symbol AZYO
Full Company Profile

Financial Performance

In 2021, AZYO's revenue was $47.39 million, an increase of 11.03% compared to the previous year's $42.68 million. Losses were -$24.83 million, 13.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for AZYO stock is "Buy." The 12-month stock price forecast is 10.71, which is an increase of 48.75% from the latest price.

Price Target
$10.71
(48.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aziyo Biologics Appoints Michelle LeRoux Williams, Ph.D as Chief Scientific Officer

Renown Pioneer in Regenerative Medicine to Lead Company's Pipeline Development Initiatives Renown Pioneer in Regenerative Medicine to Lead Company's Pipeline Development Initiatives

1 month ago - GlobeNewsWire

Aziyo Biologics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

SILVER SPRING, Md., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced the company will present at the upcoming Ina...

1 month ago - GlobeNewsWire

Aziyo Biologics Announces $25 Million Loan Facility with SWK Holdings

Provides Additional Working Capital to Further Fund Growth Initiatives Provides Additional Working Capital to Further Fund Growth Initiatives

1 month ago - GlobeNewsWire

Aziyo Biologics Co-Founder and Regenerative Medicine Pioneer, Dr. Randy Mills, appointed Chief Executive Officer

SILVER SPRING, Md., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced that Aziyo co-founder C. Randal (Randy) Mill...

1 month ago - GlobeNewsWire

Aziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022

SILVER SPRING, Md., July 28, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

2 months ago - GlobeNewsWire

Is Aziyo Biologics (AZYO) Outperforming Other Medical Stocks This Year?

Here is how Aziyo Biologics, Inc. (AZYO) and AMN Healthcare Services (AMN) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Aziyo Biologics, Inc. (AZYO) Moves 7.8% Higher: Will This Strength Last?

Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

3 months ago - Zacks Investment Research

Aziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEO

SILVER SPRING, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

3 months ago - GlobeNewsWire

Aziyo Biologics, Inc. (AZYO) Reports Q1 Loss, Tops Revenue Estimates

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of 3.23% and 6.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Aziyo Biologics Provides Business Update and Reports First Quarter 2022 Financial Results

SILVER SPRING, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated prod...

4 months ago - GlobeNewsWire

Aziyo Biologics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022

SILVER SPRING, Md., April 25, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pr...

5 months ago - GlobeNewsWire

Aziyo Biologics Announces Upcoming KOL Call Hosted by Cowen

Call to Highlight the Use and Benefits of Aziyo's CanGaroo Envelope for Implantable Electronic Devices Call to Highlight the Use and Benefits of Aziyo's CanGaroo Envelope for Implantable Electronic Devices

5 months ago - GlobeNewsWire

Aziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor Conference

SILVER SPRING, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pr...

6 months ago - GlobeNewsWire

Aziyo Biologics, Inc. (AZYO) Reports Q4 Loss, Lags Revenue Estimates

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -28.13% and 2.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Aziyo Biologics Reports Fourth Quarter and Full Year 2021 Financial Results

SILVER SPRING, Md., March 03, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pr...

6 months ago - GlobeNewsWire

Aziyo Biologics to Participate in the Cowen 42nd Annual Health Care Conference

SILVER SPRING, Md., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

7 months ago - GlobeNewsWire

Aziyo Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022

SILVER SPRING, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

7 months ago - GlobeNewsWire

All You Need to Know About Aziyo Biologics, Inc. (AZYO) Rating Upgrade to Buy

Aziyo Biologics, Inc. (AZYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

Has Aziyo Biologics, Inc. (AZYO) Outpaced Other Medical Stocks This Year?

Here is how Aziyo Biologics, Inc. (AZYO) and Doximity (DOCS) have performed compared to their sector so far this year.

7 months ago - Zacks Investment Research

Wall Street Analysts See a 123% Upside in Aziyo Biologics, Inc. (AZYO): Can the Stock Really Move This High?

The consensus price target hints at a 123.3% upside potential for Aziyo Biologics, Inc. (AZYO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni...

8 months ago - Zacks Investment Research

Aziyo Biologics to Present at the H.C. Wainwright Bioconnect Virtual Conference

SILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

9 months ago - GlobeNewsWire

Aziyo Biologics Announces Closing of $14.0 Million Private Placement

SILVER SPRING, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (the “Company”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pr...

9 months ago - GlobeNewsWire

Aziyo Biologics Announces $14.0 Million Private Placement

SILVER SPRING, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (the “Company”) today announced that it has entered into a definitive agreement to sell securities in a private placement that...

9 months ago - GlobeNewsWire

Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Misses Revenue Estimates

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -32.79% and -0.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Aziyo Biologics Reports Third Quarter 2021 Financial Results

SILVER SPRING, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

10 months ago - GlobeNewsWire